Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Conceptus CEO hired

This article was originally published in The Gray Sheet

Executive Summary

Former Bausch & Lomb President, Americas, Mark Sieczkarek, 48, is appointed president, CEO and board member of the Essure non-incisional birth control company, effective April 17. Former president and CEO Steven Bacich will become the firm's chief technology officer. The San Carlos, Calif. firm says Sieczkarek's experience in overseeing the launch of B&L's Zyoptix laser for LASIK eye surgery will serve him in marketing Essure, approved last November (1"The Gray Sheet" Nov. 11, 2002, p. 16)...

You may also be interested in...

Conceptus Essure Contraceptive Approved Three Months Post-Panel Review

FDA's approval of Conceptus' Essure non-incisional permanent birth control device includes a requirement that the company document the placement failure rate with newly trained physicians and identify factors associated with the failure, the agency notes in a Nov. 4 "talk paper" announcing the approval

Big Pharma BD Execs Tell Start-Ups: Don’t Be Afraid To Ask Us For Help

Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.

Transformation Into Viatris Not Seen As The Solution Mylan Needs

Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts